secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-06-10T23:59:59+00:00
Accession:  0001193125-22-171994
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines increases CEO Mark Goldsmith's change-in-control severance to 2x salary plus bonus
--------------------------------------------------------------------------------

- Severance multiplier raised from 1.5x to 2x for CEO Mark Goldsmith upon qualifying termination near a change in control.
- Applies to termination without cause or resignation for good reason from 3 months before to 18 months after a change in control.
- Amendment approved by Compensation Committee on June 8, 2022, and executed on June 10, 2022.
- Lump sum cash payment equals 2x annual base salary plus target annual bonus.
- No other terms of the employment agreement were changed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522171994/0001193125-22-171994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522171994/d331499d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-171994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer